Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia
- The feasibility will be evaluated in terms of toxicities, complete remission rate,
duration of complete remission, disease-free survival, and overall survival.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete remission rate, duration of complete remission, toxicities
Hawk Kim, professor
Ulsan Universtity Hospital, ROK
Korea: Food and Drug Administration